IRCCS Eugenio Medea / Associazione la Nostra Famiglia
Conegliano, Treviso, 31015, Italy
Location status: Recruiting
Location contact
Isabella Orlando, PhD
CONTACT
Leonardo Boccuni, PhD
CONTACT
NCT Number: NCT07095062
Prospective, exploratory, multicenter pilot study investigating the structural and functional connectome in patients with Friedreich's Ataxia (FRDA) using high-density electroencephalogram (HD-EEG). The aim is to identify neurophysiological biomarkers and analyze the relationship between cortical connectivity, cognitive functioning, and clinical severity, particularly in response to rehabilitation treatment.
Interested in participating?
Request Info8 year–60 year
All sexes
Interventional
Not applicable
Conegliano, Treviso, 31015, Italy
Location status: Recruiting
Isabella Orlando, PhD
CONTACT
Leonardo Boccuni, PhD
CONTACT
Friedreich's Ataxia (FRDA) is a progressive neurodegenerative disease caused by mutations in the FXN gene, resulting in a reduction in the mitochondrial protein frataxin and a dysfunction in iron homeostasis. In addition to motor and sensory impairments, FRDA also results in cognitive and emotional deficits. Pathophysiologically, it is associated with cerebellar degeneration and alterations in cerebello-cortical networks.
The present study proposes a novel HD-EEG-based approach to analyze brain activity at resting-state and during the performance of a motor task (task-based) in subjects with FRDA. Thirty patients with confirmed genetic diagnosis, age between 8 and 60 years, and SARA score <30 will be recruited. EEG recordings will be performed in resting condition and during an upper limb motor task.
In addition to neurophysiological measures, each participant will undergo a comprehensive neuropsychological evaluation, including memory, attention, language, visuospatial skills, praxis, executive functions, emotional and personality aspects. Connectivity data will be correlated with cognitive profiles and scores on the SARA and mFARS clinical scales.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will undergo high-density EEG (HD-EEG) recordings under two conditions: at rest and while performing an upper limb motor task. The data obtained will be used to reconstruct source cortical activity and derive patterns of functional connectivity, using advanced neurophysiological analysis techniques, including the Avalanche Transition Matrix (ATM). In addition, patients will complete a neuropsychological assessment and participate in an intensive multidisciplinary rehabilitation program lasting 3 to 4 weeks, depending on age. The intervention aims to assess changes in the functional organization of the brain before and after treatment, as well as one year later, in order to explore potential biomarkers of disease progression.
Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up
Characterization of alterations in the connectome derived from the HD-EEG of subjects with FRDA compared with matched controls;
Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up
Evaluation of functional connectivity as a biomarker in the evolution of FRDA
Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up
Contact information is provided by the study sponsor or research team.
IRCCS Eugenio Medea
Other
Structural-Functional Connectome and High Density Electroencephalogram: Pilot Study in Patients With Friedreich's Ataxia.
Acronym: CONNETTOMA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02497534
Ataxia, Brain Diseases
Gainesville, Florida, United States
View Trial DetailsNCT02316314
Ataxia, Brain Diseases
New York, United States
View Trial DetailsNCT07681713
Brain Diseases, Central Nervous System Diseases
View Trial DetailsNCT07635030
Brain Diseases, Central Nervous System Diseases
Philadelphia, Pennsylvania, United States
View Trial Details